Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study
ConclusionsTreatment with aCD20 or SP1-M therapies appears to be associated with a lower humoral response to vaccines against SARS-CoV-2. Vaccination prior to initiation of these DMTs should be recommended whenever possible. (Source: Neurology and Therapy)
Source: Neurology and Therapy - December 14, 2023 Category: Neurology Source Type: research
Bioequivalence Study of Two Tablet Formulations of Clonazepam 2 mg: A Randomized, Open-Label, Crossover Study in Healthy Mexican Volunteers Under Fasting Conditions
ConclusionThe test and reference formulations of clonazepam 2 mg were bioequivalent and well tolerated in healthy Mexican volunteers under fasting conditions.Protocol Authorization Number213301410B0051 (Approved on April 13, 2021). (Source: Neurology and Therapy)
Source: Neurology and Therapy - December 2, 2023 Category: Neurology Source Type: research
Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial
ConclusionsThis post hoc analysis supports the consistency of efficacy of galcanezumab across 6 months of treatment and suggests that wearing-off within the dosing interval does not occur on a population level in Japanese patients with episodic migraine.Trial RegistrationClinicalTrials.gov identifier, NCT02959177. (Source: Neurology and Therapy)
Source: Neurology and Therapy - November 7, 2023 Category: Neurology Source Type: research
Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary
AbstractNarcolepsy is associated with disrupted nighttime sleep (DNS). Sodium oxybate (SXB; Xyrem®), administered twice nightly, is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients 7 years or older with narcolepsy. Recently, low-sodium oxybate (LXB, Xywav®; for people 7 years of age and older), which contains 92% less sodium than SXB and is dosed twice nightly, and sodium oxybate for extended release (SXB-ER; Lumryz™; for adults), which contains equal sodium to SXB and is dosed once nightly, have also been approved to treat cataplexy or excessive daytime sleepi ness in narcoleps...
Source: Neurology and Therapy - November 7, 2023 Category: Neurology Source Type: research
Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
ConclusionFremanezumab appears effective as preventive migraine treatment in Japanese CM patients with or without MO while also being beneficial in reducing MO. (Source: Neurology and Therapy)
Source: Neurology and Therapy - November 7, 2023 Category: Neurology Source Type: research
Burden of Medication Overuse in Migraine: A Cross-sectional, Population-Based Study in Five European Countries Using the 2020 National Health and Wellness Survey (NHWS)
ConclusionAmong people with migraine, those who report MO face a greater humanistic burden than those without MO, irrespective of headache frequency. (Source: Neurology and Therapy)
Source: Neurology and Therapy - November 7, 2023 Category: Neurology Source Type: research
Rule-Based Identification of Individuals with Mild Cognitive Impairment or Alzheimer ’s Disease Using Clinical Notes from the United States Veterans Affairs Healthcare System
ConclusionsClinical note-based identification captured more Veterans recorded with MCI and AD than diagnostic code-based identification. (Source: Neurology and Therapy)
Source: Neurology and Therapy - November 7, 2023 Category: Neurology Source Type: research
Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
ConclusionIn Japanese patients with different migraine frequencies, erenumab treatment resulted in significant improvements in MMD, MSMD, and headache impact. This pooled analysis of data from phase 2 and 3 studies increases confidence that erenumab is efficacious in patients with high MMD, which is associated with increased disability. (Source: Neurology and Therapy)
Source: Neurology and Therapy - November 7, 2023 Category: Neurology Source Type: research
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson ’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
ConclusionFoslevodopa/foscarbidopa has the potential to provide a safe and efficacious, individualized, 24-hour/day, nonsurgical alternative for patients with PD.Trial Registration NumberClinicalTrials.gov identifier NCT03781167. (Source: Neurology and Therapy)
Source: Neurology and Therapy - November 7, 2023 Category: Neurology Source Type: research
Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment
AbstractMany biological markers have been explored in multiple sclerosis (MS) to better quantify disease burden and better evaluate response to treatments, beyond clinical and MRI data. Among these, neurofilament light chain (Nf-L), although non-specific for this disease and found to be increased in other neurological conditions, has been shown to be the most promising biomarker for assessing axonal damage in MS, with a definite role in predicting the development of MS in patients at the first neurological episode suggestive of MS, and also in a preclinical phase. There is strong evidence that Nf-L levels are increased mor...
Source: Neurology and Therapy - November 7, 2023 Category: Neurology Source Type: research
Effect of PLA2G6 and SMPD1 Variants on the Lipid Metabolism in the Cerebrospinal Fluid of Patients with Parkinson's Disease: A Non-targeted Lipidomics Study
ConclusionsOur study demonstrated that the disturbed composition and function of CSF-derived exosome lipidome during the pathological stage of PD may affect different types of sleep disorder in PD. (Source: Neurology and Therapy)
Source: Neurology and Therapy - November 7, 2023 Category: Neurology Source Type: research
Experience of Daily Life with Generalized Myasthenia Gravis: A Qualitative Investigation and Assessment of Instrument Content Validity
ConclusionThis research provides a holistic understanding of gMG signs, symptoms, and impacts experienced by patients, as observed by patients and clinicians. The conceptual model of gMG highlights the range of signs, symptoms, and impacts that adult patients with gMG experience in their everyday lives, emphasizing the humanistic impact and unmet needs. (Source: Neurology and Therapy)
Source: Neurology and Therapy - November 7, 2023 Category: Neurology Source Type: research
Letter to the Editor Regarding: “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”
(Source: Neurology and Therapy)
Source: Neurology and Therapy - November 7, 2023 Category: Neurology Source Type: research
Response to Letter to the Editor Regarding “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis”
(Source: Neurology and Therapy)
Source: Neurology and Therapy - November 7, 2023 Category: Neurology Source Type: research
Letter to the Editor Regarding “Validation of a Set of Instruments to Assess Patient- and Caregiver-Oriented Measurements in Spinal Muscular Atrophy: Results of the SMA-TOOL Study”
(Source: Neurology and Therapy)
Source: Neurology and Therapy - November 4, 2023 Category: Neurology Source Type: research
